Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

IVERIC BIO, INC.

Home Clinical Trial Sponsors and OrganizationsIVERIC BIO, INC.

IVERIC BIO, INC.

ACTIVE

1 Penn Plz, 新泽西州默瑟县, New Jersey, United Stateswww.ivericbio.comPublic163 employeesEstablished: 2007-01-01

Also known as:

ophthotech

iveric

Part of Astellas US Holding, Inc.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

18

15 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2007

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

15

83.3%

Phase 2

2

11.1%

Phase 3

1

5.6%

Trial Status Distribution

Active, not recruiting

15

83.3%

Completed

2

11.1%

Terminated

1

5.6%

Clinical Trials

Trials sponsored by this organization (18)

A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt Disease

Active, not recruiting

Jan 2021120 participants

Phase 2a open label study of Fovista¿ (anti-PDGF agent) administered in combination with anti-VEGF therapy in subjects previously treated or treatment-naive.

Active, not recruiting

Jan 202132 participants

A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneratio

Active, not recruiting

Nov 2020400 participants

A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneratio

Active, not recruiting

Nov 2020400 participants

A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneratio

Active, not recruiting

Nov 2020400 participants

A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneratio

Active, not recruiting

Oct 2020400 participants

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

Jun 2020448 participants

A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneratio

Active, not recruiting

May 2020400 participants

Page 1 of 3

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials18
Approvals
News

Back to Organizations